Benzinga's Top Upgrades
July 31, 2013 at 07:50 AM EDT
Analysts at Credit Suisse upgraded Cubist Pharmaceuticals (NASDAQ: CBST ) from “neutral” to “outperform.” The target price for Cubist Pharmaceuticals has been raised from $56 to $69. Cubist's shares closed at $57.00 yesterday. Analysts at Benchmark upgraded Open Text (NASDAQ: OTEX ) from “hold” to “buy.” The target price
